Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9613548 | 0.88 | MLNR (0.36) | SIGMAR1JAK1JAK2MEN1ALDH1A1 | |
| SCHEMBL2707640 | 0.86 | BACE1 (0.41) | BACE1BACE2 | |
| SCHEMBL9611358 | 0.86 | BACE1 (0.41) | BACE1BACE2 | |
| SCHEMBL9613550 | 0.79 | DPP8 (0.36) | BACE1BACE2SIGMAR1JAK1JAK2 | |
| SCHEMBL13017323 | 0.79 | DPP8 (0.36) | BACE1BACE2SIGMAR1JAK1JAK2 | |
| SCHEMBL9613457 | 0.79 | SIGMAR1 (0.43) | SIGMAR1 | |
| SCHEMBL9613500 | 0.78 | BCHE (0.41) | SIGMAR1 | |
| SCHEMBL9613553 | 0.76 | P2RX7 (0.41) | SIGMAR1PABPC1 | |
| SCHEMBL13017324 | 0.76 | P2RX7 (0.41) | SIGMAR1PABPC1 | |
| SCHEMBL9611499 | 0.74 | KLK7 (0.42) | KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415486-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2010138666-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | BACE1 33/4885BACE2 41/4885SIGMAR1 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.